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The nucleocapsid (N) protein of severe acute respiratory syn-
drome (SARS) coronavirus plays important roles in both viral
replication and modulation of host cell processes. New ligands
that target the N protein may thus provide tools to track the
protein inside cells, detect interaction hot spots on the protein
surface, and discover sites that could be used to develop new
anti-SARS therapies. Using mRNA display selection and
directed evolution, we designed novel antibody-like protein
affinity reagents that target SARS N protein with high affinity
and selectivity. Our libraries were based on an 88-residue vari-
ant of the 10th fibronectin type III domain from human
fibronectin (10Fn3). This selection resulted in eight independ-
ent 10Fn3 intrabodies, two that require the N-terminal domain
for binding and six that recognize theC terminus, onewithKd
1.7nM. 10Fn3 intrabodies arewell expressed inmammalian cells
and are relocalized by N in SARS-infected cells. Seven of the
selected intrabodies tested do not perturb cellular function
when expressed singly in vivo and inhibit virus replication from
11- to 5900-fold when expressed in cells prior to infection. Tar-
geting two sites on SARS-N simultaneously using two distinct
10Fn3s results in synergistic inhibition of virus replication.
The ability to detect and inhibit protein function is central to
molecular and cellular biology research. To date, phage display
andmonoclonal antibody production have been themost com-
mon routes to design reagents for protein detection and inhi-
bition, antibodies and antibody-like reagents that serve as high
affinity, high specificity molecular recognition tools (1). Totally
in vitro selection methods using alternative scaffolds are
becoming more common to produce affinity reagents with
improved and expanded functionality (2, 3). For example, ribo-
some display andmRNAdisplay enable creating 1–100 trillion-
member peptide and protein libraries that surpass immunolog-
ical and phage display diversities by 3–5 orders of magnitude
(4).
Antibodies or antibody-like molecules are important
because they can serve as diagnostics, probes for studying pro-
teins in vivo, and potential therapeutics (or surrogate ligands
for therapeutic design/screening). Regarding biology, antibod-
ies used inside living cells, denoted “intrabodies,” are appealing
because they provide an alternative to genetic knock-outs,
dominant negativemutations, andRNA interference strategies,
enabling targeting proteins in a domain-, conformation-, and
modification-specific fashion aswell as identifying hot spots for
protein interaction (5, 6). For example, green fluorescent pro-
tein-labeled intrabodies can act as molecular beacons to deter-
mine real time, live cell localization of endogenous target pro-
teins rather than non-native expression of green fluorescent
protein target fusions (7).
Although antibodies often demonstrate laudable affinity and
selectivity, these proteins are likely to be suboptimal as a gen-
eral approach to create intracellular reagents. Most notably,
antibodies contain disulfide bonds that are likely to be reduced
in the cytosol, thus impeding their proper folding and function
(8). To overcome the paucity of functional intrabodies gener-
ated by in vitro selection methods, in vivo screens may be
employed at the expense of combinatorial diversity (9). On the
other hand, it has been demonstrated that intracellular anti-
bodies can generate aggresomes, which may inhibit the ubiq-
uitin-mediated degradation pathway and promote apoptosis
(10–12).
Ideally, intrabodies would be as follows: 1) easy to produce in
a broad variety of cells; 2) stable; 3) specific; 4) high affinity; 5)
highly selective; 6) functional in intracellular environments;
and 7) noninterfering with normal cellular processes. Recently,
ribosome display has been used to generate protein affinity
reagents based on ankyrin domains (DARPins), which detect
and inhibit kinase or proteinase function in vivo (13, 14).
Although this scaffold is powerful, it is structurally very differ-
ent from antibodies as it utilizes a discontinuous binding sur-
face rather than the continuous surface generated by the CDR
loops in antibody VH and VL domains.
Our approach here has been to use mRNA display to design
disulfide-free antibody-like proteins that can be used to create
general protein targeting tools. To do this, we used a protein
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library based on the 10th fibronectin type III domain of human
fibronectin (10Fn3)3 (15, 16). The 10Fn3domainwas developed
as an antibody mimetic by Koide et al. (16) because of the fol-
lowing: 1) it is topologically analogous to the immunoglobulin
VH domain; 2) it is exceptionally stable; 3) it presents a contin-
uous protein interaction surface; and 4) it expresseswell in both
eukaryotic and bacterial cells (16). We recently described con-
struction and characterization of a 3  1013 member 10Fn3
library (15) and validated this library by developing proteins
and fluorescence resonance energy transfer sensors that recog-
nize IB in a phosphoserine-specific fashion (17). There the
selected 10Fn3 functioned in vivo, blocking proteasome-medi-
ated degradation of full-length IB efficiently.
Here we have targeted the severe acute respiratory syndrome
(SARS-CoV) nucleocapsid protein (N). SARS-CoV is a unique
member of the Coronaviridae family with only 20% sequence
identity to the closest homolog (18). There is a need for reagents
and methods that can be used to detect new infectious entities
as they arise. Indeed, the recent SARS epidemic was unex-
pected, reaching an 8% fatality rate despite the fact that coro-
naviruses typically are involved in30% of common cold infec-
tions. N protein is 422 amino acids long, phosphorylated, and
composed of two structured domains linked by a nonstructured
domain. The N-terminal domain (NTD) is a putative RNA
binding domain, and the C-terminal domain (CTD) mediates
self-association (Fig. 1A) (19, 20). The unstructured middle
domain interactswith themembrane (M) protein, anchoringM
protein to the viral core. The two structured domains act in
concert to bind genomic RNA, oligomerize, and form the final
packaged ribonucleoprotein complex.
We chose N as our target for several reasons. First, the N
protein is the most abundant protein produced by SARS virus.
Second, N plays multiple roles in vivo, including binding/pack-
aging the viral genomic RNA, mediating interactions with the
viral membrane (via the M protein), acting in genome replica-
tion, and exerting control over host cell processes (21, 22).
Finally, no therapeutic reagents currently target N protein;
therefore, new inhibitory N-directed ligands represent an
important potential new route for developing anti-SARS drugs.
After six rounds of selection, we were able to generate mol-
ecules that detect SARS N protein in vitro and modulate its
SARS replication in vivo in a domain-specific manner. The
selection yielded six high affinity molecules that recognize the
CTD and two molecules that require the NTD for binding. We
confirmed the interaction between the selected 10Fn3 proteins
and N protein both in vitro and in vivo by pulldown, co-immu-
noprecipitation, and immunofluorescence microscopy. Seven
of the 10Fn3-based intrabodies inhibit replication, ranging
from 11- to 5900-fold, recognizing at least two nonoverlapping
epitopes/hot spots in a synergistic manner. These molecules
represent new tools for detecting SARS virus, assessing N func-
tion in living cells, and identifying regions of N critical for virus
proliferation.
EXPERIMENTAL PROCEDURES
Cell Culture and Virus—293T, 293T-ACE2, and VERO cells
were cultured in Dulbecco’s modified Eagle’s medium contain-
ing 10% fetal bovine serum and 1% penicillin/streptomycin.
The 293-ACE2 is a stable cell line derived from 293T after co-
transfecting ACE2 and a puromycin resistance plasmid. Wild
type SARS-CoV Urbani strain was obtained from the Centers
for Disease Control and Prevention. Both WT SARS-CoV and
SARS-CoV Renilla luciferase recombinant virus were propa-
gated in VERO cells (23, 24). The murine -herpesvirus 68-lu-
ciferase virus (MHV-68/M3FL) was constructed by inserting
viral M3 promoter-driven firefly luciferase cassette between
genomic coordinates 746 and 747 of MHV-68 (U97553).
Plasmids—SARS-CoVN protein was cloned from the cDNA
derived from SARS-CoV-infected cell into bacteria expression
plasmid pDW363C (25). N containing the biotinylation signal
peptide tag was then subcloned into pcDNA3 (Invitrogen) for
mammalian expression with a His tag. pTAG-N was con-
structed for mammalian expression of N protein with N-termi-
nal FLAG and calmodulin-binding protein tag. N-NTD and
N-CTDwere subcloned frompcDNA3-N by PCR. The selected
10Fn3 pool 6 cDNA was cloned into pCR4-TOPO using a
TOPO TA cloning kit (Invitrogen). Selected molecules were
further subcloned into pET11 (Novagen) for bacterial expres-
sion with C-terminal His6 tag and pIRES-puro (Clontech) for
mammalian expression with C-terminal FLAG tag.
Protein Purification—The N protein target was expressed
and purified from transfected 293T cells using Lipofectamine
Plus (Invitrogen). Cells were lysed using modified RIPA buffer
(10 mM Tris, pH 8.0, 1% Nonidet P-40, 150 mM NaCl, 1 mM
EDTA) and purified with Ni2-NTA beads. N protein was bio-
tinylated in vitro using biotin ligase (Avidity) and conjugated to
streptavidin acrylamide or neutravidin-agarose beads (Pierce).
Selected 10Fn3 proteins were expressed using Escherichia coli
BL-21 (DE3) cultures induced at OD0.4 with 1 mM isopropyl
1-thio--D-galactopyranoside for 3 h at 37 °C. The proteins
were purified with Ni2-NTA beads (Qiagen).
mRNA Display—For the first round of selection, a library of
approximately 1 trillion unique DNA molecules was amplified
by PCR. For each round of selection, the PCR product was tran-
scribed by in vitro runoff transcription with T7 RNA polymer-
ase. Library RNAwas ligated with T4 DNA ligase (PerkinElmer
Life Sciences) to aDNA linker that contains puromycin at the 3
end (pF30P, 5-phospho-A21-93-ACC-Pu, where 9 is phos-
phoramidite spacer 9, and Pu is puromycin, Glen Research
Corp.). Ligationwasmediated by a splint complementary to the
3 library and 5 linker sequences (Fn-pF30P-Splint, 5-TTTT-
TTTTTTTTGGAGCCGCTACC). Ligated library mRNA was
purified by urea-PAGE and translated in vitro with rabbit
reticulocyte lysate (Red NOVA, Novagen). Fusion formation
was enhanced by addition of potassium and magnesium as
described previously (26). RNA-10Fn3 fusions were purified by
binding at 4 °C to oligo(dT)-cellulose beads (PerkinElmer Life
Sciences) in oligo(dT) isolation buffer (100 mM Tris, pH 8, 1 M
NaCl, 0.2% Triton X-100), eluted in 10 mM Tris, pH 8, at room
temperature, and desalted (Nap-25, GE Healthcare or Centri-
sep, Princeton Separations). The fusions were reverse-tran-
3 The abbreviations used are: 10Fn3, human fibronectin 10th fibronectin type
III domain; SARS-CoV, severe acute respiratory disorder coronavirus; N,
nucleocapsid protein; s2m, stem-loop 2 motif; NTD, N-terminal domain;
CTD, C-terminal domain; Ni-NTA, nickel-nitrilotriacetic acid; WT, wild type.
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scribed (Superscript II, Invitrogen) prior to affinity enrichment
with immobilized N protein. Binding and washing buffer con-
tained 1 TBS (20 mM Tris, pH 8, 150 mM NaCl) plus 0.02%
Tween 20, 0.5 mg/ml bovine serum albumin (Sigma), and 0.1
mg/ml sheared salmon sperm DNA (Sigma). After round one,
fusion pools were subjected to FLAG tag purification with anti-
FLAG M2-agarose beads (Sigma) and were eluted with 3
FLAGpeptide (Sigma). Rounds 2–6 also included a preclearing
step to remove background binders using empty beads prior to
the selection. Binding and washing were performed at 4 °C for
rounds 1–5 and at 37 °C for round 6.
In Vitro Binding Assay—For 10Fn3 pools, radiolabeled
fusions were prepared as described for the selection, except the
translations were supplemented with L-[35S]methionine (MP
Biomedicals). Fusion pools were incubatedwith ribonuclease A
(Roche Applied Science) prior to measuring binding efficien-
cies. Individual pool 6 clones were amplified from pCR4-
TOPO. Following in vitro transcription, the purified unique
10Fn3RNAproductswere translated in vitrowith rabbit reticu-
locyte lysate (RedNova, Novagen) in the presence of L-[35S]me-
thionine. Translated 10Fn3 proteins were then FLAG tag-puri-
fiedwith anti-FLAGM2-agarose beads (Sigma) using 3 FLAG
peptide for elution. Radiolabeled 10Fn3 pools and individual
pool 6 N-binding 10Fn3 proteins were incubated with immobi-
lized N protein or empty beads. After washing in selection
buffer, binding efficiencies were determined by scintillation
counting. Pool binding assays were performed at either 4 or
37 °C, as indicated. Individual clone bindings were performed
at room temperature.
Pulldown and Co-immunoprecipitation Assays—Purified
10Fn3 proteins immobilized onNi2-NTA-agarose beads were
used to pull down recombinant p-TAG-N protein from crude
293T cell lysate overnight at 4 °C. For co-immunoprecipitation,
293T cells were co-transfected with plasmids bearing His-
tagged N and FLAG-tagged 10Fn3 proteins. The harvested cell
lysate was incubated overnight at 4 °C with protein G-Sepha-
rose beads (Amersham Biosciences) conjugated with either the
anti-FLAG antibody (Sigma) to precipitate 10Fn3 proteins or
anti-mouse IgG as negative control. For domain mapping by
pulldown, themammalian N-WT, N-NTD, and N-CTDwere
immobilized on Ni-NTA beads and were used to pull down
10Fn3 proteins bearing a FLAG tag from transfected 293T cell
lysate overnight in 4 °C. The co-immunoprecipitation and pull-
down assays were performed with modified RIPA buffer and
analyzed by Western blots.
Surface Plasmon Resonance—Binding kinetics were meas-
ured by a Biacore T100 instrument using a streptavidin sensor
chip. N protein purified from 293T cells was loaded at a density
of 800 response units. Various concentrations of either Fn-N17
or Fn-N22 purified from E. coli BL21(DE3) were flowed over a
blank streptavidin chip and the N bound chip at 100l/min for
120 s and were allowed to fall off for 1 h. Kinetic data were
obtained by fitting with Biacore evaluation software.
Immunofluorescence Microscopy—VERO cells were trans-
fected in 8-well chamber slides with 10Fn3 intrabodies and
infected with SARS-CoV. Infected and noninfected cells were
fixed with 2% paraformaldehyde. The immunofluorescence
was done following the standard protocol. 10Fn3 intrabodies
were detected by anti-FLAG antibody (Sigma) and Alexa
Fluor 488 goat anti-mouse IgG (Invitrogen). The N proteins
were detected by polyclonal anti-SARS N protein antibody
(Imgenex) and goat anti-rabbit Cy3-conjugated antibody
(Invitrogen).
SARS-CoV Inhibition Assay—293T cells were transfected
with 10Fn3 intrabodies or empty plasmid and infected with
SARS-CoV Renilla luciferase as described. Renilla luciferase
was used as a reporter to correlate the virus titer of transfected
cell supernatants. Supernatants were collected from trans-
fected cells 20 h post-infection and used to infect fresh 293T-
ACE2 cells (secondary reporter cells). The secondary reporter
cells were collected at 16 h post-infection and assayed for lucif-
erase activity. Primary transfected cells were harvested after
supernatant transfer to determine relative protein expression.
All cells were collected with Passive Lysis Buffer for analysis by
Renilla luciferase assay system (Promega).
Real Time Quantitative PCR—Total RNAs were extracted
from the SARS-CoV-infected cells first by TRI Reagent
(Invitrogen), and then 10 g of the total RNA were purified by
micro-to-midi RNA purification system (Invitrogen). The
cDNAs were made from reverse transcription of 1 g of puri-
fied RNA using random hexamers and Superscript III (Invitro-
gen). Viral N gene transcripts were amplified by primers SARS/
qPCR-NF and SARS/qPCR-NR, following the standard SYBR
green quantitative PCR protocol. Standards for copy number
calculation were derived from cloning amplified PCR product.
Quantitative PCR for human -actin was done as a normaliza-
tion control using primers ACTB-5F and ACTB-3R.
RNABand Shift—A32-mer RNA composing the stem loop 2
motif was created using runoff transcription (27). The T7 pro-
moter oligonucleotide (5-TCCTAATACGACTCACTATAG)
was annealed to the template oligonucleotide (5-CTGTACC-
CTCGATCGTACTCCGCGTGGCCTCGCCTATAGTGAG-
TCGTATTAGGA) and added (500 nM) to transcription buffer
(80mMHEPES, pH 7.5, 2mM spermidine, 20mMdithiothreitol,
25 mM MgCl2 supplemented with 4 mM NTPs). Transcription
was carried out at 37 °C for 2 h. After addition of excess EDTA,
the sample was phenol/chloroform-extracted and purified by
denaturing urea-PAGE. N protein was purified as described
above and treated with DNase I and RNase A. The N protein
sample was then re-purified using Ni-NTA-agarose beads. To
generate higher protein concentrations, Fn-N10 and Fn-N17
were subcloned to create C-terminal maltose-binding protein
fusions as described previously and purified by affinity chroma-
tography (17). Binding reactions were carried out at room tem-
perature for 30 min in 1 phosphate-buffered saline. Samples
contained combinations of RNA,N, and 10Fn3 proteins at con-
centrations of 400 nM and 3.2 and 16 M, respectively. 1.7 l of
50% glycerol was added to 15-l samples, whichwere separated
on a 0.8% agarose gel stained with ethidium bromide.
RESULTS
mRNADisplay Selection—We expressed and purified N pro-
tein from eukaryotic cells to retain native phosphorylation. The
recombinant N protein was engineered with an N-terminal
His6 tag and an N-terminal biotinylation signal peptide for in
vitro biotinylation. The specific biotinylation scheme allows
Fibronectin-based Intrabodies That Target SARS-CoV N
17514 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 26•JUNE 26, 2009
directional immobilization via a specific lysine near the N ter-
minus. We confirmed the functionality of the immobilized N
protein by its ability to pull down free N protein andM protein.
For the selection of binders to N protein, we used the 10Fn3
scaffold library described previously by Olson and Roberts (15)
(Fig. 1B). Our library began with a complexity of more than 1
trillion unique sequences, each present with 10 copies. In
each round, the cDNA/mRNA-protein library was incubated
with immobilized N and washed, and the beads were amplified
via PCR (see “Experimental Procedures”). Enrichment of tar-
get-specific binders was monitored by performing a radiola-
beled pulldown assay for each round (Fig. 1C). After observing
target-specific enrichment in pool 5, the stringency of the selec-
tion was increased by performing round 6 binding and washing
at 37 °C. Pool 6 binding is very efficient with greater than 60% of
the pool remaining bound at 4 °C and 30% at 37 °C.
Pool 6 was cloned, and 18 sequences were obtained (Fig. 1E
and supplemental material). Of the 18 sequences, Fn-N22 was
the most abundant with a total of six clones. The other
sequences were represented by one (Fn-N01, Fn-N17, Fn-N08,
Fn-N11, and Fn-N15) or two clones (Fn-N06, Fn-N10, and Fn-
N20). Fn-N15 appeared nonspecific based on the presence of
three arginine and two lysine residues in the BC loop and was
not characterized further. The nine representative 10Fn3 pro-
teins were each characterized for function, and all showed a
better binding matrix bearing target than the matrix alone
(Fig. 1D).
Notably, each of the nine N-binding 10Fn3 proteins tested
had highly dissimilar sequences, arguing that each of thesemol-
ecules recognizes N in a unique manner (Fig. 1, D and E). As
expected, the binding analysis demonstrated that Fn-N22 has
the best pulldown efficiency (68%), with little background bind-
ing. In rank order, the binding of the other clones followed
Fn-N10  Fn-N15  Fn-N20  Fn-N11  Fn-N17. Fn-N06
and Fn-N08 had lower binding efficiency, whereas Fn-N01 had
a relatively high background to target binding ratio andwas not
characterized further.
Expression and Binding Validation—We next sought to
investigate the expression properties of the eight functional
10Fn3 variants (Fig. 2A). To do this, the 10Fn3 proteins were
expressed in bacteria (Fig. 2A, bottom panel) and used to pull
down FLAG-tagged N protein (Fig. 2A, upper panel). Although
expression levels varied greatly, all eight 10Fn3 proteins were
able to pull down theNprotein, with Fn-N10 and Fn-N22 being
most efficient (Fig. 2A). We next tested expression and binding
of the selected 10Fn3 proteins in eukaryotic cells (293T cells,
Fig. 2B). All eight of the 10Fn3 intrabodies (Fig. 2B, top panel)
are able to co-express in these cells with N protein (Fig. 2B, 2nd
panel). FLAG-based immunoprecipitation of the 10Fn3 pro-
teins is efficient (Fig. 2B, 3rd panel), and three of the 10Fn3s
demonstrated efficient co-immunoprecipitation of the N pro-
tein (Fn-N10, Fn-N17, and Fn-N20) (Fig. 2B, bottom panel).
Using enzyme-linked immunosorbent assay, Fn-N17 and Fn-
N20 were also demonstrated to function as well or better when
compared with a high affinity anti-N monoclonal antibody
(supplemental Fig. S1).
We next explored which regions of N were bound by the
eight functional 10Fn3 domains. To do this, the full-length N
FIGURE 1.mRNAdisplay selection of 10Fn3 binders to N. A, representative diagram of dimerized N protein. B, 10Fn3 domain. Seventeen residues in the BC
and FG loops are randomized in our trillionmember combinatorial library. C, radiolabeled in vitro binding assay formonitoring binder enrichment in selection
pool 3, 5, and 6. The data are represented as the percentage of radioactive 10Fn3 proteins bound to the beads with N protein (N) or beads only (N). The
pulldown assays were performed at 4 °C. Pool 6 binding was also performed at 37 °C.D, radiolabeled in vitro binding assay for individual binders. 9 represent-
ative binders were chosen from pool 6 for the pulldown assay as described in C. E, sequence alignment of the nine chosen binders.
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(WT; residues 1–422), an N-terminal deletionmutant (NTD;
residues 182–422), and a C-terminal domain fragment (CTD;
residues 248–422) were purified from 293T cells (Fig. 2C) and
immobilized on nickel beads. The selected 10Fn3 proteins were
expressed in mammalian cells with a C-terminal FLAG epitope
for detection. Of the eight 10Fn3 proteins tested, Fn-N17 and
Fn-N20 are pulled down only by the full-length N protein.
Therefore, interaction with the N-terminal RNA binding
domain is required for binding by Fn-N17 and Fn-N20 (Fig.
2D). The other six N-binders could be pulled down by all three
N protein variants, indicating that they bind to the C-terminal
self-association domain. It is interesting to note that the pull-
down of all six CTD-specific binders was more efficient with
constructs lacking the NTD.
Binding Affinity—We chose Fn-N22, a CTD binder, and Fn-
N17, an NTD-dependent binder, to test the binding affinities
achieved with this selection using surface plasmon resonance
(Fig. 3). The N protein was prepped and purified with N-termi-
nal specific biotinylation, allowing for directional immobiliza-
tion on a Biacore streptavidin chip. For Fn-N22, the selection
winner, the association rate constant was 2.17  107 M1 s1,
and the dissociation rate constant was 0.037 s1, resulting in an
equilibrium dissociation constant (Kd) of 1.7 nM. For Fn-N17,
the association rate constant was 8.71  105 M1 s1, and the
dissociation rate constant was 0.062 s1, resulting in a Kd 72
nM (2 0.3 response unit2 for each fit). The relative affinities
FIGURE 2. Expression and binding of selected 10Fn3 proteins. A, N protein
pulldown by bacteria-derived 10Fn3 proteins. Ni-NTA bead-conjugated binders
were used to pull downmammalian N protein from transfected cell lysates. The
pulldown was analyzed by Western blot using antibody against FLAG tag for N
and antibody against His6 tag for 10Fn3 proteins. In, 2.5% of input lysate; Ctr,
pulldowncontrolusingunconjugatedNi-NTAbeads.B,co-immunoprecipitation
(CoIP) ofNproteinwith10Fn3proteins. 4%of input lysatewasanalyzedbyWest-
ernblot usingantibodyagainstNandantibodyagainst FLAG for 10Fn3proteins.
9th lane is Fn-N17 transfection only control. 10th lane is N protein transfection
onlycontrol.C,expressionof full-lengthNproteinandtruncatedmutants.The left
panel is aWesternblotanalysisusingantiHis6 tagantibody. Thedomaindiagram
on the right depicts the region of truncation.WT, full length; NTD, N-terminal
domain deletion mutant; CTD, C-terminal domain; MBD, M protein binding
domain. D, domain specificity of N-binding 10Fn3 proteins. Immobilized His6-
taggedN-WT,NTD, andCTDwereused topull down10Fn3proteins from293T
cell lysate. Thepulldownswere analyzedbyWesternblot usingantibodyagainst
FLAG-tag for 10Fn3 proteins. Input, 4% of input lysate; Control, unconjugated
Ni-NTA beads control.
FIGURE 3. Affinity of Fn-N17 and Fn-N22 for SARS N, determined by sur-
face plasmon resonance. Raw data are presented in black; red is the fitted
curve.
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were consistent with the relative in vitro pulldown efficiencies
(68 versus 30%).
Cellular Localization—We next explored whether localiza-
tion of the selected 10Fn3 intrabodies changes in response to
the presence of N protein and whether these two proteins co-
localizewithinmammalian cells (Fig. 4). Todo this, we began by
transfecting Fn-N10, Fn-N17, and Fn-N20 inVEROcells. In the
absence of SARSN, each of these intrabodies shows substantial
nuclear localization (Fn-N10 shown; Fig. 4), as shown by co-
localization with 4,6-diamidino-2-phenylindole stain, and
gave diffuse fluorescence. Upon infection with SARS-CoV, the
three intrabodies dramatically altered their localization,
becoming cytosolic, and showed good overlap with SARS N
localization. We also conducted similar experiments wherein
the 10Fn3 intrabody and SARSNproteinwere both transfected
into cells. Similarly, in these experiments we also observed
movement of the intrabody to the cytosol and co-localization
with SARS N (data not shown).
Inhibition of Viral Production—We next sought to test
whether any of our selected 10Fn3 intrabodies affected viral
production because of their interactions with SARS N. For-
mally, overexpression of our intrabodies could block virus pro-
duction by a specific mechanism (e.g. direct interaction with N
that alters some critical function) or by a nonspecific mecha-
nism (e.g. by generically impairing general cellular functions).
We began by measuring viral production with a variant of
SARS-CoV bearing the Renilla luciferase gene (RL) in open
reading frame 7 (24). Importantly, with this SARS-CoV strain,
virus titer directly correlateswith luciferase activity and enables
themeasurement of relative virus quantity over a large dynamic
range. We first collected supernatant from SARS-CoV/RL-in-
fected cells that express 10Fn3 intrabodies. To determine the
relative virus titer, this supernatant was then used to infect sec-
ondary reporter cells, which were assayed 16 h post-infection.
All seven of the tested 10Fn3 strains inhibit viral production
using the luciferase SARS-CoV variant (Fig. 5A), ranging from
11-fold to more than 5900-fold. Indeed, both C-terminal
domain binding clones (FnN17 and FnN20) and N-terminal
domain binding clones (Fn-N06, Fn-N10, Fn-N11, FnN15, and
Fn-N22) were capable of inhibiting SARS-CoV production.
Furthermore, inhibition of viral production was demonstrated
to be dose-dependent (supplemental Fig. S2). The viral inhibi-
tion does not appear to be a function of the 10Fn3 protein
scaffold, as transfection and overexpression of Fn38 (a ran-
domly chosen, nonfunctional clone characterized previously
(15)) show a modest 2-fold decrease in virus production.
We next evaluated whether 10Fn3 intrabodies that recog-
nize nonoverlapping epitopes could inhibit virus production
synergistically. To test this, the two NTD-dependent binders
(Fn-N17 and Fn-N20) and the highest affinity CTD binder (Fn-
N22) were co-transfected into cells (Fig. 5B). These experi-
ments were done at lower DNA concentration than the single
fibronectin experiments (Fig. 5A) to enable us to accurately
demonstrate the synergistic inhibition generated by two potent
inhibitors. At this concentration, expression of Fn-N17, Fn-
N20, and Fn-N22 alone inhibits viral production 4-, 2-, and
6.6-fold, respectively. Co-expression of the two NTD binders
(Fn-N17 and Fn-N20) together had an additive effect on virus
inhibition (7.1-fold), consistent with simply increasing the
inhibitory intrabody concentration. Interestingly, co-expres-
sion of Fn-N17with Fn-N22 or Fn-N20with Fn-N22 resulted in
135–300-fold inhibition, consistent with both combinations of
10Fn3 intrabodies recognizing unique sites simultaneously and
exerting cooperative inhibition of SARS-CoV production.
Inhibition of SARS-CoVGene Expression—Our virus produc-
tion assays involve two steps (Fig. 5) and are able to detect even
FIGURE 4. Localization of 10Fn3 intrabodies in SARS-CoV-infected cells
by immunofluorescencemicroscopy. Fn-N10-, Fn-N17-, and Fn-N20-trans-
fected VERO cells were eithermock-infected or infected by SARS-CoVWT at a
multiplicity of infection of 0.1 and were fixed at 16 h post-infection. 4,6-
Diamidino-2-phenylindole (DAPI) stains used for the nucleus. Green, 10Fn3;
red, N protein.
FIGURE 5. Luciferase assay to determine inhibition of viral production.
10Fn3 or mock-transfected 293T-Ace2 cells were infected at a multiplicity of
infection of 0.5, and supernatants were collected 20 h post-infection. The cell
supernatants were used to infect reporter cells to determine relative viral
titers. Data are represented as the fold reduction in luciferase activity relative
to control. A, 10Fn3 intrabodies inhibit viral production. B, cooperative inhi-
bition by 10Fn3 intrabodies.
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very small amounts of virus. On the other hand, they are an
indirect measure of virus replication, as the virus is propagated
in the second step. We sought to directly measure the ability of
the 10Fn3 intrabodies to inhibit gene expression in the original
infected cells (Fig. 6). We did this in two ways. First, we moni-
tored the inhibition of luciferase production directly using
SARS-CoV/RL in 293T-Ace cells (Fig. 6A). Second, we directly
measured mRNA production using quantitative reverse tran-
scription-PCR with wild type SARS-CoV in the same cell line
(Fig. 6B).
Both experiments show thatNTD- andCTD-binding 10Fn3s
inhibit gene expression directly (Fig. 6, A and B). Looking at
luciferase production (Fig. 6A), Fn-N17, Fn-N22, and Fn-N10
give the best inhibition, ranging from 4.8- to 29-fold compared
with the no fibronectin control. Fn-N11, Fn-N15, and Fn-N20
gave reduced but measurable inhibition, ranging from 1.6- to
2.3-fold. Importantly, the nonfunctional clone, Fn38, gave no
inhibition, indicating that expression of an exogenous fibronec-
tin has little effect on our assay. We note that four inhibitors
tested (Fn-N10, Fn-N17, Fn-N20, and Fn-N22) displayed inhi-
bition in a dose-dependent manner (supplemental Fig. S3).
We next used quantitative reverse transcription-PCR to
measure the effect of our selected 10Fn3s on viral mRNA levels
(specifically, the subgenomic mRNA; Fig. 6B). Similar to the
luciferase assay, the best inhibitors were Fn-N20, Fn-N22, and
Fn-N10, which decrease viral mRNA levels from 2.8- to 13-
fold. Fn-N17 and Fn-N06 showed less inhibition than the Fn38,
the nonfunctional control. Northern blot analysis confirmed
that other SARS transcripts were reduced in the same trend as
the open reading frame N subgenomic mRNA (data not
shown). Furthermore,Western blot analysis demonstrated that
Fn-N22, Fn-N10, Fn-17, and (to a lesser extent) Fn-N20 pre-
vent accumulation of SARS structural proteins (supplemental
Fig. S4).
Finally, we wished to demonstrate that the inhibition we
observed was specific to the SARS virus. For example, if the
selected 10Fn3s aggregated or misfolded, they might generally
disrupt cellular function, thereby inhibiting virus production.
To address this, we transfected each of our 10Fn3s into cells and
then performed a luciferase-based inhibition assay with the
herpesvirus variant MHV-68/M3Luc. In these experiments,
only one of our eight selected binders (Fn-N08) inhibited
MHV-68/M3Luc expression (data not shown). Thus, we did
not include Fn-N08 in our inhibition or co-localization studies
(Figs. 4–6).We also demonstrated that the best inhibitors (Fn-
N10, Fn-N22, Fn-N17, and Fn-N20) do not effectMHV-68 cap-
sid protein expression (supplemental Fig. S5).
Effect of 10Fn3 Proteins on RNA Binding—N protein nor-
mally exists as a dimer and is capable of binding and band-
shifting SARS RNA. To conclude this work, we sought to deter-
mine the effect of our selected 10Fn3 proteins on N protein
RNA binding as measured by band shifts. To do this, we used a
32-mer single-stranded RNA segment of the SARS stem loop 2
motif (s2m) previously used by Chen et al. (28). Fig. 7 demon-
strates that Fn-N10 and Fn-N17 do not inhibit N binding to
SARS s2m RNA. However, both the CTD binding Fn-N10 and
theNTD-dependent binder Fn-N17 have the effect of resolving
the diffuse, low mobility N-RNA complex to a well defined
band. This indicates that the 10Fn3 proteins are able to bind the
FIGURE 6. 10Fn3 intrabodies inhibit viral gene expression. A, 10Fn3 intra-
bodies inhibit luciferase expression. 293T-Ace2 cells were transfected with
each 10Fn3 intrabody and infected with SARS-CoV/RL virus at multiplicity of
infection 0.5. Renilla luciferase activities were assayed at 20 h post-infection.
The fold inhibition of luciferase expression is defined as the ratio of luciferase
activity fromcells transfectedwith empty plasmid relative to cells transfected
with 10Fn3 intrabodies. B, 10Fn3 intrabodies inhibit viral gene transcription.
Quantitative PCR was performed using SARS-CoV NmRNA. The amount of N
transcript was normalized to actin transcript control. Data are represented as
fold reduction of calculated copy number.
FIGURE 7. Effect of 10Fn3 inhibitors on N binding to RNA. The binding
reactions contain mixtures of s2m RNA (0.4 M), nuclease-treated N (3.2 M),
and 10Fn3-maltose-binding protein fusions (16M). 3rd lane includes 1g of
bovine serumalbumin. Binding reactionswere run on a 0.8% agarose gel and
stained with ethidium bromide.
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N-RNAcomplex, forming a ternary complex. The nature of this
ternary complex is not clear. N protein exists as a dimer in
solution and is able to form larger oligomeric states at higher
concentrations and in the presence of nucleic acid (28–30). The
diffuse N-RNA band may be due to the presence of multiple
oligomerization states, whereas the resolving effect of the
10Fn3 inhibitors may be indicative of either a single conforma-
tion state or a soluble, high molecular weight complex of N
protein, s2m RNA, and 10Fn3.
DISCUSSION
Our data demonstrate that directed evolution by mRNA dis-
play enabled designing of at least eight novel high affinity pro-
tein reagents targeting the SARS nucleocapsid protein (Fig. 1,D
and E; Fn-N22, Fn-N17, Fn-N06, Fn-N06, Fn-N20, Fn-N08,
Fn-N11, and Fn-N15). The pool showed a high fraction of bind-
ing (25%) even at physiologic temperature and salt. Biochem-
ically, the best binder, Fn-N22, was themost abundantmember
of the cloned sequences (6 of 18 cloned) indicating that the pool
was converging to a selection winner. None of the distinct
clones are related by homology, indicating each is an independ-
ent solution to the binding problem we presented the library.
Each of the loop sequences contains a high representation of
aromatic and polar residues, typical of protein interaction sur-
faces (31). Given the relatively small number of pool members
sequenced (18 total), it is likely that there are many more than
eight independent binders in our round 6 pool.
The selected 10Fn3 proteins were functional, well behaved,
and able to be expressed in a number of formats. In addition to
the reticulocyte lysate expression system used for library con-
struction, 10Fn3 proteins were expressed in bacteria andmam-
malian cells, including 293T and VERO cells (Figs. 2–6).
Interestingly, our selection revealed two distinct binding
sites on N for 10Fn3 recognition, the NTD and CTD (Fig. 1A).
Six of the eight 10Fn3s bind the CTD alone (Fn-N06, Fn-N08,
Fn-N10, Fn-N11, Fn-N15, and Fn-N22), whereas the other two
(Fn-N17 and Fn-N20) require the NTD to bind. Structurally,
the NTD and CTD are connected by unstructured regions (see
Fig. 1A, schematic) and have been reported to be noninteracting
(32). On the other hand, three of our CTD binders (Fn-N08,
Fn-N10, and Fn-N22) show markedly improved binding to N
constructs lacking the N-terminal domain (Fig. 2D), indicating
the NTD may partially occlude the binding site on the CTD.
One CTD binder (Fn-N22) and one NTD-dependent binder
(Fn-N17) were analyzed for affinity. The monovalent Fn-N22
and Fn-N17 bind to N protein with high affinity, similar to or
better than the larger Fv region of monoclonal antibodies
(Kd  1.7 and 72 nM, respectively) (33). Even though this
affinity is high, it is likely that affinity maturation and evolu-
tion could improve these affinities further, opening the
potential that these binders could be used in ultra-sensitive
detection platforms.
A remarkable aspect of our work is that at least four of the
selected 10Fn3 proteins (Fn-N10, Fn-N17, Fn-N20, and Fn-
N22) specifically and dramatically inhibit SARS-CoV replica-
tion when transiently expressed in mammalian cell culture.
Several points are worth noting. Generally, overexpression of
the 10Fn3s is well tolerated inside the cell lines tested. 10Fn3
expression is relatively diffuse, with a higher density in the
nucleus. Also, the 10Fn3 proteins are re-localized to the cyto-
plasm by N, demonstrating the potential for these molecules as
tools for real time visualization (Fig. 4). Finally, the majority of
the selected 10Fn3s (7/8 functional proteins) do not inhibit cel-
lular function as measured in a relatively stringent assay, the
ability to propagate an unrelated virus, herpesvirus.
Functionally, ligands targeting the CTD (Fn-N10 and Fn-
N22) appear to have a larger inhibitory effect compared with
theNTD-dependent binders. Furthermore, combining anNTD
and CTD binder results in synergistic inhibition (Fig. 5B). Our
findings are reminiscent of the common antiviral mixture ther-
apeutic strategy. Our findings are reminiscent of common anti-
viral mixture therapeutic strategies, where multiple small mol-
ecules drugs are used to target two or more key viral enzymatic
functions. Here we have demonstrated that targeting two dis-
tinct protein surfaces of the nonenzymatic nucleocapsid pro-
tein also provides cooperative inhibition of virus production, a
novel and intriguing result.
Finally, we sought to characterize how our selected 10Fn3s
might affect N function. The NTD of N is thought to mediate
binding to the genomicRNAessential for the formation of ribo-
nucleoprotein complex (20). To determine whether 10Fn3
intrabodies inhibit SARS replication by effecting nucleic acid
binding, we tested RNA band shifts using a portion of the SARS
s2m. Both Fn-N10, the best inhibitor and a CTD binder, and
Fn-N17, an NTD-dependent binder, do not compete with the
RNA for binding to N. Bothmolecules have the effect of resolv-
ing the band formed by the complex. Although the band shift is
well resolved, its low mobility makes it difficult to conclusively
determine the effect of 10Fn3s on N oligomerization. Based on
the data, our working hypothesis is that the 10Fn3 proteins
reduce the structural and oligomeric heterogeneity of the
N-RNA complexes.
This study demonstrates the utility of using mRNA display
selections to generate selective, high affinity 10Fn3-based pro-
teins that target specific cellular components. 10Fn3 intrabod-
ies are able to be expressed in bacteria for biophysical charac-
terization and are stable in mammalian cells, advantages over
the commonly used antibody scaffold. Importantly, no in vivo
screen was required to filter the resulting pool for binders that
function inside the cell. Of the eight intrabodies tested, seven
function efficiently to block SARS replication and do not dis-
rupt mammalian cellular function (Fig. 2B).
Used inside cells, 10Fn3s provide a complementary tool to
commonly used methods for the analysis of proteins in vivo
such as gene knock-outs and small interfering RNA. The N
binders described in this study may thus be useful for future
studies of SARS virus. For example,N bindersmay shed light on
key N protein-host cell protein interactions during various
stages of the virus life cycle.Our results demonstrate that 10Fn3
intrabodies enable in vivo visualization of N. Therefore, the
10Fn3s may enable analyzing the fate of N and the ribonucleo-
protein complex in real time during the various stages of the
virus life cycle. This would be especially useful during the initial
stages of virus entry, where reverse genetics cannot be easily
applied because infectious viral particles may not be generated
without functional viral capsid or envelope proteins. Finally,
Fibronectin-based Intrabodies That Target SARS-CoV N
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the biological neutrality of the 10Fn3s implies that combin-
ing two or more inhibitors may be useful clinically as an
approach toward improving gene therapy-based preventative
interventions for persistent viral diseases.
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